ANI Pharmaceuticals Inc

NASDAQ:ANIP  
30.99
+0.47 (+1.54%)
Other Pre-Announcement

Ani Pharmaceuticals Reports First Quarter 2022 Results Provides Purified Cortrophin® Gel Net Revenue Guidance And Full-Year 2022 Total Company Net Revenue Guidance Of $295 Million To $315 Millio

Published: 05/10/2022 11:04 GMT
ANI Pharmaceuticals Inc (ANIP) - Ani Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million.
Q1 Adjusted Non-GAAP Loss per Share $0.12.
Q1 GAAP Loss per Share $1.27.
Q1 Revenue $64.5 Million Versus $54.5 Million.
Ani Pharmaceuticals - Cash and Cash Equivalents $76.9 Million As of March 31, 2022.
Sees 2022 Adjusted Non-GAAP Diluted Earnings per Share Between $1.34 and $1.62.
Sees FY Total Net Revenue Between $295.0 Million and $315.0 Million.